4D Molecular Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
4D Molecular Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2020 to Q3 2024.
  • 4D Molecular Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $6.49M, a 42.3% increase year-over-year.
  • 4D Molecular Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $24.5M, a 35.1% increase year-over-year.
  • 4D Molecular Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $19.7M, a 14.9% increase from 2022.
  • 4D Molecular Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $17.1M, a 24.1% increase from 2021.
  • 4D Molecular Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $13.8M, a 177% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $24.5M $6.49M +$1.93M +42.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $22.5M $6.07M +$1.1M +22.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $21.4M $5.97M +$1.75M +41.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $19.7M $5.91M +$1.57M +36.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $18.1M $4.56M +$42K +0.93% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $18.1M $4.97M +$647K +15% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $17.4M $4.22M +$288K +7.32% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $17.1M $4.35M +$615K +16.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $16.5M $4.52M +$597K +15.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $15.9M $4.32M +$506K +13.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $15.4M $3.93M +$1.6M +68.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $13.8M $3.73M +$2.01M +117% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 $11.8M $3.92M +$2.78M +242% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $9.01M $3.82M +$2.78M +268% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $6.23M $2.33M +$1.25M +115% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $4.98M $1.72M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 $1.15M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $1.04M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $1.08M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.